NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
Becton Dickinson & Co. BDX
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY12 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$21.8B
▲ 8.2% vs FY2024
Dividend streak
12 yrs
Raised every year since 2014
EPS · FY25
$5.82
Dividend / sh · FY25
$4.16
Payout · FY25
71%
ROE · FY25
6.5%
Net margin · FY25
7.7%
Dividend coverage
1.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 21.8B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
8 cents of every revenue dollar became profit this year.
Per share
USD 5.82
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.4 times — the rest stayed in the company.
Profitability
6.5%
Return on equity, FY2025
ROE
Operating margin11.8%
Net margin7.7%
Return on assets3.0%
Each USD of equity produced 7 cents of profit this year.
Returned to shareholders
USD 2.2B
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.2B
Net buybacksUSD 1.0B
Share of profit130.9%
Consecutive raises12 years
USD 1.2B in dividends and USD 1.0B in buybacks — 131% of the year's profit, so the payout drew on cash built up earlier.
Growth
+6.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.0%
+6.3%
+7.8%
+7.8%
Net income
−1.9%
+13.9%
+9.2%
+1.6%
EPS, diluted
−0.3%
+16.5%
+5.7%
+0.4%
Dividend / share
+6.1%
+5.7%
+5.7%
+7.1%
Returned to shareholders
+11.6%
+16.4%
+16.3%
+5.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 55.3B
total assets, end of FY2025
Total assetsUSD 55.3B
EquityUSD 25.4B
CashUSD 641.0M
Gross debtUSD 19.2B
Net debtUSD 18.5B
Current ratio1.11×
Net debt stands at 73% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
21.8
20.2
19.4
18.9
19.1
16.1
17.3
16.0
12.1
12.5
10.3
8.4
8.1
7.7
7.6
7.1
7.0
6.9
6.3
Operating income $B
2.6
2.4
2.1
2.3
2.2
0.9
1.8
1.5
1.5
1.4
1.1
1.6
1.3
1.6
1.7
1.6
1.6
1.5
1.2
EBITDA $B
5.0
4.7
4.4
4.5
4.5
3.0
4.0
3.5
2.6
2.5
2.0
2.2
1.8
2.1
2.2
2.1
2.1
2.0
1.6
Income tax $B
0.2
0.3
0.1
0.1
0.1
0.1
−0.1
0.9
−0.1
0.1
0.0
0.3
0.2
0.4
0.4
0.5
0.4
0.4
0.3
Net income $B
1.7
1.7
1.5
1.8
2.1
0.9
1.2
0.3
1.1
1.0
0.7
1.2
1.3
1.2
1.3
1.3
1.2
1.1
0.9
EPS, diluted $
5.82
5.86
4.94
5.88
6.85
2.71
3.94
0.60
4.60
4.49
3.35
5.99
6.49
5.59
5.62
5.49
4.99
4.46
3.49
Dividend / sh $
4.16
3.80
3.64
3.48
3.32
3.16
3.08
3.00
2.92
2.64
2.40
2.18
1.98
·
·
1.48
1.32
1.14
·
Payout %
71
65
75
61
50
117
80
298
62
58
70
36
30
31
28
26
26
25
27
ROE %
6.5
6.6
5.8
7.3
8.8
3.9
5.9
1.8
10.7
13.2
11.4
23.5
28.2
26.1
24.8
24.9
24.4
22.8
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
61 of 61
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed